Beta Blocker Meets Stricter Criterion
NEW ORLEANS—Two pooled analyses of the newest beta blocker, nebivolol, demonstrate that it is effective as once daily monotherapy in stage 1 and 2 hypertension using more stringent criteria than normal to measure BP control.
Your Email Address:
Recipient(s) Email Address:
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
Include a message (optional):
The e-mail address(es) that you supply to use this service will only be used to send the requested article.